v3.26.1
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Operating expenses:    
General and administrative $ 5,593,078 $ 1,551,168
Research and development 265,570 245,956
Total operating expenses 5,858,648 1,797,124
Loss from operations (5,858,648) (1,797,124)
Other income:    
Net gain from change in fair value of derivative liability instrument 2,574,971
Gain from change in fair value of forward contract liability 380,442
Amortization of deferred offering cost (496,948)
Interest income 29,583 28,709
Other income 176,520
Total other income 2,664,568 28,709
NET LOSS $ (3,194,080) $ (1,768,415)
Basic net loss per common share $ (0.12) $ (0.07)
Diluted net loss per common share $ (0.12) $ (0.07)
Weighted-average common shares outstanding, basic 27,716,045 26,643,432
Weighted-average common shares outstanding, diluted 27,716,045 26,643,432